India set to approve its first Covid vaccine; all india goes dry run

 India set to approve its first Covid vaccine; all india goes dry run


A dry run for covid-19 vaccination is being conducted by all state and union territory administrations today to test the linkages between planning and implementation and to identify the challenges

 

Kerala: State Health Minister KK Shailaja reviews dry run for COVID-19 administration at Government Hospital, Peroorkada in Thiruvananthapuram. She says, "The mock drill is over here. Everything went smoothly. The exercise is being conducted in 4 districts".

 

source : www.livemint.com

India drug regulator approves AstraZeneca COVID vaccine

 India drug regulator approves AstraZeneca COVID vaccine

 

India's drug regulator is set to approve on Friday a coronavirus vaccine developed by Oxford University and AstraZeneca, for emergency use, according to news agency Reuters reported. The expert committee set up by Drugs Controller General of India (DCGI) V.G. Somani to vet vaccine proposals, met for the second time this week, recommended emergency approval for Oxford-AstraZeneca COVID-19 vaccine. British-Swedish drugmaker inked an agreement with Serum Institute of India to produce 1 billion doses of its experimental vaccine for lower-and-middle income countries.
 

Countries with relatively basic health infrastructure have high hopes for a shot that, unlike Pfizer’s, can be stored and transported under normal refrigeration, rather than supercooled to -70 degrees Celsius (-94 Fahrenheit). 

 

 

Source : Reuters

How Indian chemical industry struggles to reduce dependency on china

The Indian sector has long been dependent on China to imports.The industry expert believe that domestic production suppliers from US, EU, Japan, South Korea, South Africa and others can fill the space by the Chinese suppliers.

Indian chemical industry

In the case of chemicals, the best options come from India or South Korea, chemical players now see an excellent business opportunity for India.



Day 54 of India lock down a high dependency on china has one opportunity in India. The chemical industry a sector worth 1000cr. and covering more then 30000 commercial goods is struggling. 
Indian chemical industry is nothing without any help from china.Indian businesses can diversify their vendors and supply chains so that the overall risk.

This is particularly important when it comes to a situation like a pandemic, where much of the world is seeing large scale disruptions. Big players says he has alternative supplies from Europe and part of Asia such as Korea, Japan etc. The trick here is to have many suppliers to hedge your bets against large scale disruption. Also, as the Covid-19 virus progresses, different regions find themselves in different levels of lock down.

Opportunity :

Due to corona scare, the world will not rely on China alone now. When we talk to foreign customers, we get a sense that they have now started giving a hard look to Chinese supplies. They are now increasingly looking at alternate from china.
Many of our exhibitors have very good products, but they need some distributors or some type of agents here who can help them to grow their business.

The 'Make in India' campaign as one which is intended to produce in India for consumers across the globe. 
South African manufacturers to use the opportunity of growing their businesses by partnering with India.

Also Read : 

Allopathic drugs to treat coronavirus disease 

Allopathic drugs to treat coronavirus disease

Allopathic treatment 

Corona virus emerged in December 2019 and then spread rapidly worldwide. Scientists are endeavouring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19). Some promising results have been achieved thus far.

Antivirals including interferon α (IFN-α), lopinavir/ritonavir, chloroquine phosphate, ribavirin, and arbidol have been included in the latest version of the Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia.

The specific method for administration of IFN-α is vapor inhalation at a dose of 5 million U (and 2 mL of sterile water for injection) for adults, 2 times/day. The dosage of lopinavir/ritonavir is 400 mg/100 mg for adults, 2 times/ day. Ribavirin should be administered via intravenous infusion at a dose of 500 mg for adults, 2 to 3 times/ day in combination with IFN-α or lopinavir/ritonavir. Chloroquine phosphate is orally administered at a dose of 500 mg (300 mg for chloroquine) for adults, 2 times/ day. Arbidol is orally administered at a dose of 200 mg for adults, 3 times/day. The duration of treatment is no more than 10 days.

Favipiravir is a drug that attract attention. Favipiravir was approved for treatment of novel influenza.This drug is currently undergoing clinic trials in treating COVID-19.

Remdesivir is another potential drug for treatment of COVID-19. Animal experiments indicated that remdesivir can effectively reduce the viral load in lung tissue of mice infected with MERSCoV, improve lung function, and alleviate pathological damage to lung tissue.

Studies have also revealed some other drugs may have potential efficacy in treating COVID-19. One is darunavir, which is a second-generation of HIV-1 protease inhibitor.

Also read :
How to Corona Treatment from the Homeopathic + Ayurveda

Phase-3 clinical trials on antiviral drug Favipiravir for COVID-19 by Glenmark in India

Company estimates that the study would be completed by August 2020, Glenmark Pharmaceuticals has initiated Phase-3 clinical trials in India on antiviral drug Favipiravir, for which it received approval from India’s drug regulator DCGI in late April 2020. 

Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government & private hospitals in India. 

Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. The molecule, if commercialised, will be marketed under the brand name ‘FabiFlu’ in India.

The data from these trials will point in a clearer direction with regard to COVID-19 treatment. Company’s effort is to launch a treatment for COVID-19 patients as soon as possible and control the spread of the pandemic. Treatment duration is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation.

Also read : 

How to Corona Treatment from the Homeopathic + Ayurveda

How to Corona Treatment from the Homeopathic + Ayurveda

Top 2 treatment of corona :

Coronavirus is a common virus which causes colds, influenza-like symptoms and pneumonia. COVID-19 is a new strain which means fewer people already have immunity to it. It appears to have the most severe effect on the elderly and people with existing medical conditions – particularly those with respiratory problems. There are no standard scientific trials available for homeopathic, or ayurvedic treatment of this coronavirus strain.

Homeopathic Medicine -COVID – 19

Homeopathic medicines have been used extensively for flu-like symptoms and in epidemics around the world. If you decide to take a homeopathic medicine, this should be in addition to the various measures and should not be your only approach. Selection of the most appropriate homeopathic medicine is based on an individual’s unique symptoms. However, Gelsemium 30c and Bryonia 30c are commonly used for flu-like symptoms and have a long-established, traditional usage over many years.

The AYUSH ministry India recommended that homeopathic medicine Arsenicum album 30 could be taken empty stomach daily for three days as a prophylactic medicine against the infection. The Ayush Ministry declared Arsenicum Album-30 as a "preventive' against COVID-19. On the basis of research done by Dr Rajan Sankaran, has backed Camphor 1M as a potential medicine for COVID-19.

Ayurvedic Medicine -COVID – 19

Ministry of Ayush starts clinical trials for Ashwagandha and 4 other Ayurvedic herbs for coronavirus treatment. In a recent positive development, Ministry of Ayush, in collaboration with the Council of Scientific & Industrial Research (CSIR) has started clinical trials testing formulation of four important Ayurvedic herbs in fighting the novel coronavirus. The medicines under study include ashwagandha, guduchi, yasthimadhu, peepli and another formulated drug, 'Ayush 64'.

Also Read : 
Phase-3 clinical trials on antiviral drug Favipiravir for COVID-19 by Glenmark in India